CD274 and neoplasm: The anti‐PD‐1/anti‐PD‐L1 immune checkpoint blockade therapy disrupts the PD‐1/PD‐L1 interaction and reactivates the anti‐tumor T‐cell‐mediated cell cytotoxicity by binding to the inhibitory PD‐1 receptor on TILs and PD‐L1 on tumor cells, respectively.